Sorry without IDE approval there is no plausible way for RDGL to continue. RDGL is an FDA play, nothing more. Only thing that matters is IDE approval. Yes, if RDGL has to do an offering now before IDE submission, the dilution will be massive. The last July terms of more than 9% of company at $0.07/share average were bad enough, especially considering how badly MK is squandered those funds on IsoPet expansion at expense of Radiogel IDE progress.
Market Data 
Markets 
AI
